Cancer Control最新文献

{"title":"Assessing Sun Protection Policies in Texas School Districts Located in Counties With the Lowest and Highest Melanoma Risk: Content Analysis and Cross-Sectional Study.","authors":"Nabeel Ahmad, Brooke Bartley, Stephanie Zhang, Madison M Taylor, Karl Schrader, Kehe Zhang, Hung Quoc Doan, Cici Bauer, Kelly C Nelson, Jennifer Cofer","doi":"10.1177/10732748251352702","DOIUrl":"10.1177/10732748251352702","url":null,"abstract":"<p><p>IntroductionSchool policy can encourage sun safe habits, such as wearing hats and applying sunscreen. However, sun safety policies (SSP) have not been formally assessed for Texas independent school districts (ISDs), particularly in counties with the highest melanoma incidence relative risk (RR). This study aims to assess the presence, strength, and intent of SSPs across Texas ISDs located in counties with the highest and lowest melanoma incidence. We also identify factors correlated with stronger SSP.MethodsEleven components of SSPs from 102 ISDs were evaluated in this cross-sectional study by examining school district websites, official documents, social media, media appearances, statements by school officials, and the Texas Education Agency's online database. Coders were trained to score each policy's content, presence, and strength.ResultsPolicies for sunscreen use and hats existed in 94% (n = 96) and 92% (n = 94) of ISDs, respectively. In counties with the highest melanoma incidence RR, 30% (n = 15) and 44% (n = 22) of ISDs allocated resources for sun safety and outdoor shade, compared to 2% (n = 1) and 3% (n = 2) in low-risk counties. No ISDs had SSPs on UV protective clothing, accountability, or modeling sun safety behaviors. SSP strength was positively correlated with percentage of school nurses (ρ = 0.564, <i>P</i> < 0.001), community median household income (ρ = 0.431, <i>P</i> < 0.001), percentage of female students (ρ = 0.461, <i>P</i> < 0.001), and tax rate (ρ = 0.366, <i>P</i> = 0.0002). Negative correlations were found with percentage of central staff administration (ρ = -0.523, <i>P</i> < 0.001) and graduation rates (ρ = -0.335, <i>P</i> < 0.001).ConclusionOur findings underscore the need for interventions to strengthen SSPs across Texas.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251352702"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics and Survival in Patients with Brain Metastases From Pancreatic Cancer: A Retrospective Observational Study.","authors":"Susan Haag, Derek Cridebring","doi":"10.1177/10732748251347844","DOIUrl":"10.1177/10732748251347844","url":null,"abstract":"<p><p>IntroductionBrain metastasis (BM) is an inauspicious finding in patients with pancreatic cancer, which significantly increases morbidity and mortality. The presentation is rare, and thus, outcomes on brain metastases from pancreatic cancer are limited.MethodsThis retrospective monocentric analysis included the electronic medical records of patients ≥ 18 years presenting with BM from pancreatic cancer. Clinical, demographic, and overall survival (OS) data were analyzed. Brain imaging (computed tomography, and magnetic resonance imaging) was used for BM diagnosis. OS was calculated from the date of diagnosis to either the date of last follow-up or death. Cox regression on OS time was used with an indicator variable for patients who ultimately developed a BM.ResultsBrain metastases was diagnosed in 34 (3.7%) patients with pancreatic cancer treated in our institution. Of the BM patients: 7 (22%) were non-White; 16 (47%) were female; the median age was 69; 35% were diagnosed at Stage II and III; and 65% were diagnosed at Stage IV. BM was the first diagnosed metastasis in 14 (41%) of the patients; in 5 individuals (15%) BM were detected within the first 100 days of pancreatic cancer diagnosis. OS from BM diagnosis was 9 months (95% CI [6.92,17.86]). The adjusted hazard ratio for patients with BM was .91(95% CI [.88, .94]; <i>P</i> = 0.60], which was not significant.ConclusionsDue to the low incidence of BM in pancreatic cancer, identification of disease remains a current challenge. In this study, we found that BM from pancreatic cancer may be the first sign that the cancer has spread. Using advanced neuroimaging early may help physicians diagnose these metastases sooner and possibly improve survival. With a larger cohort size, the findings may be potentially impactful for clinicians and patients. Prospective, multicentric studies are warranted to identify prognostic factors for treatment and survival.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251347844"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12138211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144217367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of E-Health Use on Cancer Screening Mediated Through Cancer Worry and Fatalism: A Cross-Sectional Study of Older Adults.","authors":"Yu Zheng, Jiazheng Zayn Wang, Yingxia Zhu, Xinshu Zhao","doi":"10.1177/10732748251355831","DOIUrl":"10.1177/10732748251355831","url":null,"abstract":"<p><p>IntroductionCancer has been one of the major causes of death among older adults. Cancer screening is key for early detection, which may help prevent or alleviate cancer. E-health platforms have been a main discriminator of cancer-related knowledge. The Health Belief Model indicates an association between individual behaviors, intentions, and other psychological factors. Understanding the psychological mechanisms that mediate the effect of E-health use (EHU) on cancer screening intention is crucial for cancer prevention and treatment among older adults.MethodsCross-sectional data were from the National Trends in Health Information Survey 6 (HINTS6). Respondents aged 65-74 years were selected for the study, and the final sample size, excluding missing values, was 925. This study used a parallel mediation model to analyze the mediating role of psychological mechanisms through cancer worry and cancer fatalism. Regression analysis was conducted using SPSS to test the parallel mediation model.ResultsThe study found a direct (<i>b</i> = .25, <i>b</i>_<i>p</i> = .25, <i>P</i> < .001) positive association between E-health use and cancer screening intentions. In addition, this study revealed a parallel indirect association between E-health use and cancer screening intentions mediated by cancer fatalism (<i>b</i> = .003, <i>b</i>_<i>p</i> = .003, 95% CI [.001, .004]) and cancer worry (<i>b</i> = .05, <i>b</i>_<i>p</i> = .05, <i>SE</i> = .002, 95% CI [.04, .05]).ConclusionThis study highlights the importance of EHU in promoting cancer screening intentions among older adults in the United States. Access to electronic health information can reduce cancer fatalism and increase cancer worry, ultimately leading to greater interest and intention to undergo cancer screening. These findings have implications for healthcare providers and policymakers aiming to improve cancer screening rates among older adults.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251355831"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12230283/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144576807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Essential Nature of Social Work in Cancer Control.","authors":"Brad Zebrack, Anao Zhang, Lauren V Ghazal, Nina Francis-Levin, Rachel E Brandon","doi":"10.1177/10732748251353081","DOIUrl":"10.1177/10732748251353081","url":null,"abstract":"<p><p>The conditions in which people are born, live, learn, work, play, worship, and age affect a range of health, functioning, and quality-of-life outcomes, and contribute to social needs across the cancer control continuum. To address these needs, advance the quality of cancer care, and achieve health equity, cancer care clinicians must possess comprehensive knowledge and skills to mitigate the effects of social determinants of health on patient outcomes. This knowledge should also encompass an understanding of how racism, sexism, and discrimination - along with exposures to trauma - also influence patient behaviors and outcomes, given evidence of their effects on population health. For over 100 years, social workers have comprised an essential workforce that is duly educated and trained to identify social needs and improve patient outcomes within the context of health care service delivery, and cancer care in particular. Oriented to an ecological framework, social workers are adept at identifying and mitigating the negative effects of the social determinants of health on individual knowledge, attitudes, beliefs, and behaviors, with the intent of improving results for people at risk for or diagnosed with cancer. Social workers are professionally trained for organizing communities, understanding and intervening upon social systems (including families, organizations, and institutions), providing emotional support and mental health counseling, and advocating for programs and policies that best serve patients, families, and communities. Thus, social workers play a critical role in service delivery across the cancer control continuum.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251353081"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179445/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Non-Inferior Randomized Trial of Neoadjuvant Endocrine Therapy Compared to Neoadjuvant Chemotherapy in Premenopausal Patients With Hormone-Responsive and HER2-Negative Lymph Node-Negative Breast Cancer.","authors":"Chongshan Gu, Yingjian He, Nan Zhang, Yiqiang Liu, Jinfeng Li, Tianfeng Wang, Tie Fan, Zhaoqing Fan, Tao Ouyang","doi":"10.1177/10732748251339958","DOIUrl":"10.1177/10732748251339958","url":null,"abstract":"<p><p>ObjectivesNeoadjuvant endocrine therapy (NET) has demonstrated efficacy in postmenopausal patients with hormone-responsive and HER2-negative breast cancer. However, few data are available on NET in premenopausal women. This trial was designed to compare the effectiveness of neoadjuvant chemotherapy (NCT) with NET in premenopausal patients with hormone-responsive, HER2-negative, and lymph node-negative breast cancer.MethodsIn this prospective, randomized study, premenopausal patients with hormone-responsive, HER2-negative, and lymph node-negative breast cancer were recruited. The enrolled patients were randomly assigned (1:1) to receive either NCT or NET with goserelin and tamoxifen, followed by goserelin and anastrozole. The primary purpose was to evaluate the non-inferiority of NET to NCT using a clinical response rate assessed by ultrasound.ResultsA total of 68 patients were assigned to receive either NCT (n = 31) or NET (n = 37). The clinical response rate was 16.1% for NCT and 35.1% for NET (estimated difference 19.0%, 95%CI: -1.1%-39.1%, non-inferior <i>P</i> = 0.002). The rates of breast-conserving surgery were not significantly different between the NCT and NET groups (90.3% vs 83.8%, <i>P</i> = 0.494).ConclusionsA 35.1% clinical response rate was observed in premenopausal patients after NET. However, this study was underpowered to conclude the non-inferiority of NET to NCT because of its early closure.Trial registrationClinicalTrials.gov NCT02535221.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251339958"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12062642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatitis B Virus Reactivation in Patients With HBV-Related Advanced Hepatocellular Carcinoma Undergoing Lenvatinib and Camrelizumab Treatment.","authors":"Bi Sheng, Dong Wang, Jingjing Wang","doi":"10.1177/10732748241309046","DOIUrl":"10.1177/10732748241309046","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate hepatitis B virus (HBV) reactivation and its effect on tumor response and survival outcomes in patients with HBV-related advanced hepatocellular carcinoma (HCC) undergoing lenvatinib plus camrelizumab treatment.</p><p><strong>Methods: </strong>216 patients with HBV-related advanced HCC receiving lenvatinib and camrelizumab were enrolled. Overall survival (OS), progression-free survival, and tumor response were evaluated. Univariate and multivariate analyses were performed to determine risk factors for HBV reactivation.</p><p><strong>Results: </strong>HBV reactivation occurred in 24 patients (11.1%). It was associated with poor survival and tumor response in these patients. Undetectable DNA levels, the absence of antiviral therapy, and high ALT levels were identified as vital risk factors for HBV reactivation. After receiving or adjusting the antiviral strategy, tumor response improved in patients with HBV reactivation.</p><p><strong>Conclusions: </strong>HBV reactivation could occur in patients with HBV-related HCC, treated with lenvatinib and camrelizumab, worsening tumor response and patient survival. Regular monitoring of the indicators of HBV infection and effective antiviral treatments are recommended for these patients to prevent severe complications.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748241309046"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Linking LEDGF/p75 Overexpression With Microsatellite Instability and KRAS Mutations: A Small-Scale Study in Colorectal Cancer.","authors":"Victoria Liedtke, Thomas Wartmann, Wenjie Shi, Ulf D Kahlert","doi":"10.1177/10732748251313499","DOIUrl":"10.1177/10732748251313499","url":null,"abstract":"<p><strong>Introduction: </strong>Colorectal cancer (CRC) ranks third in men and second in women, with 153,020 new cases and 52,550 deaths in 2023, and with a projected incidence of 2.2 million new cases by 2030 due to lifestyle changes and enhanced diagnostic capabilities. Identification and analysis of new biomarkers, like lens epithelium-derived growth factor splice variant of 75 kDa (LEDGF/p75), which is known to play a crucial role as stress-related oncogene, can make a significant contribution in facilitating early CRC detection.</p><p><strong>Methods: </strong>This study analyzed the expression of LEDGF/p75 and the ubiquitin E2 conjugating enzyme UBC13 in 15 CRC tissue samples and adjacent non-tumor tissues. All patient samples underwent NGS-based mutation analysis beforehand. The western blot technique was used for protein analysis, and the results were further validated using mRNA expression data from 521 patient samples from the TCGA database.</p><p><strong>Results: </strong>LEDGF/p75 expression was significantly elevated in nearly all tumor tissue samples compared to adjacent tissue (11/15, 73.3%). Additionally, the UBC13 enzyme, a key regulator in the degradation of signaling molecules, was also increased in most tumor tissue samples (9/15, 60.0%). Co-overexpression of LEDGF/p75 and UBC13 was evident in 6/6 patients. Patients with KRAS and MSH2 mutations showed a 75% and 100% correlation with LEDGF/p75 overexpression, respectively.</p><p><strong>Conclusion: </strong>This study confirms the upregulation of LEDGF/p75 in CRC and shows its correlation with KRAS and MSH2 mutations. The interaction of LEDGF/p75 with DNA damage response proteins may contribute to drug resistance and increased tumor aggressiveness. LEDGF/p75's potential as a prognostic biomarker independent of lymph node involvement or CEA levels highlights its potential in personalized therapy, and warrants further research into its therapeutic targeting.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251313499"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11837075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143450359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shooting for the Moon: Can We Cut Cancer Mortality in Canada By 50% By 2050?","authors":"Keaton Banik, Yibing Ruan, Mariet M Stephen, John M Hutchinson, Chantelle Carbonell, Matthew T Warkentin, Andrew Coldman, Rochelle Garner, Hawre Jalal, Darren R Brenner","doi":"10.1177/10732748251319485","DOIUrl":"10.1177/10732748251319485","url":null,"abstract":"<p><strong>Introduction: </strong>The United States of America reignited their Cancer Moonshot Initiative in 2022 with an ambitious goal to reduce cancer mortality by 50% over the next 25 years. In this study, we estimated how and whether a similar cancer control initiative could be achieved in Canada.</p><p><strong>Methods: </strong>We used the OncoSim microsimulation suite to address three questions: (1) what is the expected mortality from cancer in Canada by 2050 given the current trends?; (2) what would be the maximal impact on reducing cancer mortality with prevention and increased screening activities? and, (3) if a 50% reduction in projected cancer mortality could not be achieved through the primary and secondary intervention efforts, what additional advancements and discoveries would be needed to fill the \"lunar gap\"? We modeled the joint impact of risk-factor reduction and screening, as well as the independent effects of prevention and screening alone, on projected cancer mortality.</p><p><strong>Results: </strong>Our models suggest that there will be an expected 133,395 cancer deaths in 2050 in Canada. Approximately 33% of these cancer deaths could be prevented by risk-factor reduction and increased screening programs by the year 2050. This would leave a \"lunar gap\" of about 16%-17% that would need to be bridged with novel discoveries in cancer risk prevention, early detection, and treatment.</p><p><strong>Conclusion: </strong>While current knowledge and implementation of prevention and screening would have a considerable impact on a Canadian cancer moonshot, additional efforts are needed to implement cancer control initiatives and fuel additional discoveries to fill the gap.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251319485"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11822815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Immunotherapy Responses in Neuro-Oncology for Glioblastoma and Brain Metastases: A Brief Review Featuring Three Cases.","authors":"Neyran Kertmen, Gozde Kavgaci, Serkan Akin, Gokcen Coban, Ahmet Ilkay Isikay, Gozde Yazici","doi":"10.1177/10732748251322072","DOIUrl":"10.1177/10732748251322072","url":null,"abstract":"<p><strong>Introduction: </strong>Recent advancements in immunotherapy have offered new possibilities for treating aggressive glioblastoma (GBM) and brain metastases. However, evaluating treatment responses remains complex, prompting the development of the immunotherapy-specific Response Assessment in Neuro-Oncology (iRANO) criteria. Herein, we present case reports illustrating the intricacies of interpreting imaging changes post-immunotherapy, emphasizing the need for a comprehensive approach to assessing treatment effectiveness.</p><p><strong>Case reports: </strong>Case 1 discusses a 41-year-old male with GBM, highlighting the challenges of differentiating tumor progression from treatment-induced pseudoprogression. Case 2 discusses a 45-year-old female with brain metastatic malignant melanoma, presenting radiological evidence of progressive disease while undergoing nivolumab treatment. Case 3 discusses a 37-year-old male with GBM, where radiological evidence indicates progressive disease while receiving pembrolizumab treatment.</p><p><strong>Management and outcomes: </strong>In case 1, we discussed the challenges of distinguishing true tumor progression from treatment-induced pseudoprogression, leading to the continuation of the same treatment due to pseudoprogression. In case 2, post-surgery pathology revealed radionecrosis and treatment-related changes, guiding the continuation of nivolumab therapy. Case 3 involved a pathologically confirmed progression, and the patient received best supportive care due to his performance status.</p><p><strong>Discussion: </strong>Despite aggressive treatment regimens, the prognosis for GBM patients remains poor, underscoring the necessity for innovative therapeutic strategies. Immunotherapy holds promise in reshaping the treatment landscape for GBM and brain metastases, but further research and refinement of assessment criteria are crucial. Throughout our cases, we discuss the iRANO criteria, developed to overcome the limitations of the RANO criteria in capturing immunotherapy responses, particularly pseudoprogression.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251322072"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829293/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Contributing to Late Breast Cancer Diagnosis at the Brazzaville University Hospital in 2020, Congo: A Cross-Sectional Analytic Study.","authors":"Michel Ilboudo, Sylvain Honoré Woromogo, Dagnagnéwendé Dieudonné Kaboré, Nina Assanatou Jumelle Zerbo, Jean Bernard Nkoua Mbon","doi":"10.1177/10732748241270634","DOIUrl":"10.1177/10732748241270634","url":null,"abstract":"<p><strong>Objectives: </strong>Breast cancer is leading the cancer incidence and mortality ranks worldwide. Currently, breast cancer represents 30.1% of all cancers occurring in women in Congo. In sub-Saharan Africa, breast cancer is diagnosed delayed in 70% of cases. The purpose of this work is to study the epidemiological aspects of patients with late diagnosis of breast cancer at the Brazzaville University Hospital, Congo.</p><p><strong>Methods: </strong>We carried out a cross-sectional analytic study in the medical oncology service of the University Hospital of Brazzaville. We used systematic, exhaustive sampling. Logistic regression was used for data analysis, and <i>P</i> values ≤5% were considered significant.</p><p><strong>Results: </strong>Data for 182 patients were collected. Delay in diagnosis represented 91.21% of cases. Delay in diagnosis was significantly associated with lack of finance (<i>P</i> = 0.011) and with breast cancer stages greater than 2 (<i>P</i> < 0.001), but the proximity to the center was suggestive. Multivariate analysis revealed an association between diagnostic delay and proximity to the center (<i>P</i> = 0.025) as well as with breast cancer stages greater than 2 (<i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>The delay in breast cancer diagnosis widely discussed in the literature remains relevant in Congo. Routine screening, the construction of a cancer center and its optimal equipment, and the subsidy of care are all critical factors for battling delayed breast cancer diagnosis in Congo.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748241270634"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143053937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}